Check-Cap Ltd. (NASDAQ: CHEK) is a clinical stage medical diagnostics company leading the development of the first ingestible imaging capsule that utilizes low-dose X-rays for CRC screening. The Check-Cap device requires no bowel preparation or invasive procedures, and is designed … Continue reading →

Cesca Therapeutics Inc. (NASDAQ: KOOL) is focused on three target markets: cellular therapeutics; medical/diagnostic device development and commercialization; and cell manufacturing and banking. Cesca’s lead therapeutic technology platform, SurgWerks (an intraoperative rapid system for harvesting, selection/purification, testing, and delivering a … Continue reading →

Cerulean Pharma, Inc. (NASDAQ: CERU) is focused on making nanoparticle-drug conjugates (NDCs) designed to target rumors, reduce toxicity and enable combinations. The Cerulean team is committed to developing products to improve treatment options for people living with cancer. The company … Continue reading →

Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company, is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The company’s lead program is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently … Continue reading →

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is developing agents to detect, treat and monitor a broad spectrum of cancers. With the ability to attach imaging and therapeutic agents to its proprietary delivery platform – a novel phospholipid ether (PLEs) platform technology … Continue reading →

Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer. Celator’s proprietary technology platform, CombiPlex, enables the rational design and rapid evaluation of … Continue reading →

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. Catalyst is developing Firdapse (Amifampridine Phosphate, or 3,4-diaminopyridine phosphate) for the treatment of LEMS, a rare neuromuscular, autoimmune … Continue reading →

Catalyst Biosciences, Inc. (NASDAQ: CBIO) is a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions in the fields of hemostasis. Catalyst’s most advanced program, an improved next-generation coagulation Factor VIIa variant, has successfully … Continue reading →

CASI Pharmaceuticals, Inc. (NASDAQ: CASI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs. Part of its strategy is to leverage its expertise and resources in North America and … Continue reading →

Cardiome Pharma Corp. (NASDAQ: CRME) is an integrated, commercial, specialty pharmaceutical company dedicated to the development and commercialization of new therapies that will improve the health and quality of life of patients. The company strives to find innovative medicines that … Continue reading →